MDT

87.67

-1.52%↓

VEEV

234.11

-1.12%↓

A

116.65

-1.95%↓

HQY

86.99

-1.99%↓

PDCO

31.23

-0.03%↓

MDT

87.67

-1.52%↓

VEEV

234.11

-1.12%↓

A

116.65

-1.95%↓

HQY

86.99

-1.99%↓

PDCO

31.23

-0.03%↓

MDT

87.67

-1.52%↓

VEEV

234.11

-1.12%↓

A

116.65

-1.95%↓

HQY

86.99

-1.99%↓

PDCO

31.23

-0.03%↓

MDT

87.67

-1.52%↓

VEEV

234.11

-1.12%↓

A

116.65

-1.95%↓

HQY

86.99

-1.99%↓

PDCO

31.23

-0.03%↓

MDT

87.67

-1.52%↓

VEEV

234.11

-1.12%↓

A

116.65

-1.95%↓

HQY

86.99

-1.99%↓

PDCO

31.23

-0.03%↓

Search

Bristol-Myers Squibb Co.

Închisă

SectorSănătate

60 1.9

Rezumat

Modificarea prețului

24h

Curent

Minim

59.45

Maxim

60.01

Indicatori cheie

By Trading Economics

Venit

-1.1B

76M

Vânzări

442M

12B

P/E

Medie Sector

14.05

73.239

EPS

1.67

Randament dividend

4.06

Marjă de profit

0.616

Angajați

34,100

EBITDA

-1.9B

2.6B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+1.52% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

4.06%

3.06%

Următoarele câștiguri

24 apr. 2025

Data viitoare de dividende

1 mai 2025

Următoarea dată ex-dividende

4 apr. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-744M

120B

Deschiderea anterioară

58.1

Închiderea anterioară

60

Sentimentul știrilor

By Acuity

43%

57%

125 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Bristol-Myers Squibb Co. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 mar. 2025, 10:13 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11 mar. 2025, 10:13 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

6 feb. 2025, 12:13 UTC

Câștiguri

Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook

14 mar. 2025, 09:30 UTC

Top știri

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

11 mar. 2025, 02:26 UTC

Achiziții, Fuziuni, Preluări

Abecma Is an Immunotherapy Indicated for Treatment of Relapsed or Refractory Multiple Myeloma >TSVT

11 mar. 2025, 02:26 UTC

Achiziții, Fuziuni, Preluări

Stockholders Owning About 5.3% of 2seventy Bio Shares Have Agreed to Tender All Their Shares >TSVT

11 mar. 2025, 02:26 UTC

Achiziții, Fuziuni, Preluări

2seventy Bio CEO: Rationale for Deal Clear, in Line With Focus on Unlocking Value of Abecma >TSVT

11 mar. 2025, 02:23 UTC

Achiziții, Fuziuni, Preluări

2seventy Bio Stock Will No Longer Trade on Nasdaq After Closing of Deal, Expected in 2Q >TSVT

11 mar. 2025, 02:22 UTC

Achiziții, Fuziuni, Preluări

2seventy Bio's Board Unanimously Recommends Stockholders Tender Shares in Offer >TSVT

11 mar. 2025, 02:21 UTC

Achiziții, Fuziuni, Preluări

Bristol Myers Deal Represents 88% Premium to 2seventy Closing Price of $2.66 on March 7 >TSVT

11 mar. 2025, 02:21 UTC

Achiziții, Fuziuni, Preluări

Bristol Myers to Acquire 2seventy Bio Shares at $5.00 Each in All-Cash Deal for Equity Value of About $286M >TSVT

11 mar. 2025, 02:19 UTC

Achiziții, Fuziuni, Preluări

2seventy Bio Enters Into Definitive Agreement to Be Acquired by Bristol Myers Squibb

28 feb. 2025, 12:00 UTC

Top știri

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6 feb. 2025, 15:35 UTC

Câștiguri

Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD

6 feb. 2025, 13:56 UTC

Câștiguri

Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%. -- IBD

6 feb. 2025, 13:25 UTC

Top știri
Câștiguri

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6 feb. 2025, 12:00 UTC

Câștiguri

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

6 feb. 2025, 11:59 UTC

Câștiguri

Bristol-Myers Squibb 4Q Gross Margin 61.0% >BMY

6 feb. 2025, 11:59 UTC

Câștiguri

Bristol-Myers Squibb 4Q Rev $12.3B >BMY

6 feb. 2025, 11:59 UTC

Câștiguri

Bristol-Myers Squibb 4Q Net $72M >BMY

6 feb. 2025, 11:59 UTC

Câștiguri

Bristol-Myers Squibb 4Q EPS 4c >BMY

6 feb. 2025, 11:59 UTC

Câștiguri

Bristol-Myers Squibb 4Q Adj EPS $1.67 >BMY

6 feb. 2025, 11:59 UTC

Câștiguri

Bristol Myers Squibb: Expanding Existing Strategic Productivity Initiative to Include About $2B in Additional Annualized Cost Savings by the End of 2027 >BMY

6 feb. 2025, 11:59 UTC

Câștiguri

Bristol Myers Squibb 4Q International Revenue Rose 5% to $3.7B >BMY

6 feb. 2025, 11:59 UTC

Câștiguri

Bristol Myers Squibb 4Q U.S. Revenue Rose 9% to $8.6B >BMY

6 feb. 2025, 11:59 UTC

Câștiguri

Bristol Myers Squibb 4Q Legacy Portfolio Revenue $5.98B, Down 4% >BMY

6 feb. 2025, 11:59 UTC

Câștiguri

Bristol Myers Squibb: 4Q Growth Portfolio Revenue Primarily Due to Higher Demand for Reblozyl, Breyanzi, Camzyos, Yervoy and Opdualag >BMY

6 feb. 2025, 11:59 UTC

Câștiguri

Bristol Myers Squibb 4Q Rev $12.34B >BMY

6 feb. 2025, 11:59 UTC

Câștiguri

Bristol Myers Squibb: 4Q Legacy Portfolio Revenue Lower Vs Yr-Ago Primarily Due to Impact of Generics on Sprycel, Revlimid, Abraxane and Pomalyst, Partially Offset by Higher Demand for Eliquis >BMY

6 feb. 2025, 11:59 UTC

Câștiguri

Bristol Myers Squibb: 2025 Rev Outlook Reflects Near-Term Impact of Generics Across Revlimid, Pomalyst, Sprycel and Abraxane >BMY

Comparație

Modificare preț

Bristol-Myers Squibb Co. Așteptări

Obiectiv de preț

By TipRanks

1.52% sus

Prognoză pe 12 luni

Medie 60.93 USD  1.52%

Maxim 70 USD

Minim 37 USD

În baza a 16 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBristol-Myers Squibb Co. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

16 ratings

5

Cumpărare

10

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

59.535 / 60.13Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

125 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.